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 Background : We aimed to evaluate right ventricle (RV) function in children with 
primary nephrotic syndrome (PNS).
 Methods: RV hemodynamics were evaluated by Doppler echocardiography in 50 
children with PNS (aged 2.5−12 years), either at PNS onset ( n = 37) or relapse 
( n = 13), and in 50 normal controls. Heart rate, stroke volume, cardiac output, RV end-
diastolic and end-systolic volume, RV ejection fraction, RV end-diastolic pressure, 
RV peak systolic and end-systolic pressure were determined from pressure-volume 
loops. The maximal rates of RV pressure upstroke and fall (dP/d t max and dP/d t min , 
respectively) were calculated. Effective pulmonary arterial elastance was calculated 
as end-systolic pressure divided by stroke volume. Plasma tumor necrosis factor- α 
(TNF- α ) and insulin-like growth factor 1 (IGF-1) were also measured.
 Results: RV end-diastolic pressure was increased by an average of 20% in 39 of the 
patients with PNS, whereas RV ejection fraction was reduced by an average of 15% 
compared with controls ( p  <  0.05 for both). Cardiac output and stroke volume were 
maintained, indicating compensation at the expense of increased RV end-diastolic 
and end-systolic volumes and increased RV filling pressure ( p < 0.05). Plasma TNF- α 
was elevated in patients with PNS (326  ±  117 kU/L  vs. 75 ±  23 kU/L, p < 0.05); IGF-1 
was similar in PNS patients and controls.
 Conclusion: Right ventricle function was impaired in children with PNS. The char-
acteristics were unrelated to blood pressure and IGF-1, but may be correlated with 
TNF- α and disease duration. Further studies are needed to evaluate the etiology 
and clinical implications of this abnormality. 
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right ventricle function 
 1. Introduction 
 There is an increased incidence of heart disease in 
patients with chronic primary nephrotic syndrome 
(PNS), which may be attributable to the malnutrition 
and activated inflammatory state associated with 
the sustained proteinuria. PNS is also associated 
with hypercoagulability and an increased tendency 
for thromboembolism. 1,2 The reported incidence 
of thromboembolic complications ranged from 
1.8% to 6.6% in children with PNS. 1,2 Although 
thromboembolism may occur anywhere, deep vein 
thrombosis and pulmonary embolism are the most 
frequently encountered manifestations in the clin-
ical setting, and may be correlated with right ven-
tricle (RV) function. Another report3 has suggested 
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that a higher frequency of serious cardiac com-
plications, particularly cardiomyopathy and con-
gestive heart failure, occur in children with focal 
segmental glomerulosclerosis (FSGS). The authors 
speculated that the immune mechanism responsi-
ble for the development of FSGS may also affect 
the heart. 3 Gerald et al 4 studied the vascular fun-
ction of the peripheral circulation in patients with 
nephrosis, and suggested that patients with ne-
phrosis had abnormal endothelium-dependent but 
preserved endothelium-independent dilation of the 
brachial artery following an ischemic stimulus. 
Dyslipoproteinemia is probably responsible for en-
dothelial dysfunction in the conduit arteries in pa-
tients with nephrosis, and could form the basis for 
the increased risk of cardiovascular disease in these 
patients. 4 
 In this study, we evaluated RV function in chil-
dren with PNS using Doppler echocardiography. We 
suggest that protein wasting and systemic inflam-
matory activation during PNS may contribute to 
cardiac remodeling and dysfunction. 
 2. Methods 
 2.1. Subjects 
 Fifty consecutive children (36 males, 14 females) 
with PNS at onset or relapse admitted to our ne-
phrology unit were prospectively studied from January 
2002 to January 2004. The age range was 2.5−12 
years ( mean ±  SD , 6.6 ±  3.4 years). PNS was defined 
by heavy proteinuria (urinary protein > 1 g/m 2 /day), 
hypoalbuminemia [serum albumin < 2.5 g/dL (25 g/L)], 
hypercholesterolemia and edema. 5 The initial treat-
ment comprised 2 mg/kg/day (maximum 60 mg/day) 
of prednisone given orally in three divided doses for 
4 weeks, followed by therapy on alternate days 
for another 4 weeks. The daily dose was then tapered 
for 4−6 weeks and finally stopped. Response was 
defined as disappearance of proteinuria ( < 4 mg/m 2 /
day on 3 consecutive days). Patients who still had 
proteinuria at the end of 4 weeks of prednisone 
treatment were considered to be steroid resistant. 
In steroid-resistant patients and those with frequent 
relapses, intravenous pulse methylprednisolone or 
cyclophosphamide were used. 6 Fifty age- and sex-
matched normal subjects from a local school or 
kindergarten served as controls. These subjects had 
normal blood pressure (BP), no clinical electrocar-
diographic (ECG) or echocardiographic evidence of 
cardiovascular disease, and no evidence of pulmo-
nary disease. Informed consent was obtained from 
the patients and controls or their guardians. The 
study was approved by the Hospital Human Investi-
gation Review Board. 
 2.2. Echocardiography 
 Echocardiography was performed using a Toshiba 
SSH-140 color Doppler ultrasound system (Toshiba 
Corporation, Tokyo, Japan) with transducers of 
3.75 MHz or 5 MHz, as appropriate for children or 
adolescents. A complete echocardiographic exami-
nation was performed to exclude the possibility of 
congenital heart disease. Later measurements were 
performed using the machine’s incorporated anal-
ysis package. RV pressure and volume signals were 
recorded to quantify general hemodynamic condi-
tions. Heart rate, stroke volume, cardiac output, 
RV end-diastolic volume, RV end-systolic volume, RV 
ejection fraction, RV end-diastolic pressure, RV peak 
systolic pressure, and RV end-systolic pressure were 
determined from pressure-volume loops. Stroke work 
was obtained as the area of the pressure-volume 
loop, and the maximal rates of RV pressure up-
stroke and fall (dP/d t max  and dP/d t  min , respectively) 
were calculated. 7 Effective pulmonary arterial 
elastance, as a measure of RV afterload, was cal-
culated as end-systolic pressure divided by stroke 
volume. 
 2.3. Laboratory study 
 Concentrations of plasma tumor necrosis factor- α 
(TNF- α ) and insulin-like growth factor-1 (IGF-1) were 
measured using commercial enzyme-linked immu-
nosorbent assay kits (Quantikine; R&D Systems Inc., 
Minneapolis, MN, USA), according to the manufac-
turer’s specifications. A high sensitivity kit (Quan-
tikine HS; R&D Systems Inc) was used to measure 
TNF- α and IGF-1 immunoactivity. 
 2.4. Clinical and ECG study 
 Twelve-lead ECG, BP and chest radiographs were 
recorded. Blood samples were collected for coagu-
lation assays, platelet counts, and analysis of pro-
thrombin time and biochemical indicators of renal 
disease (proteinuria, serum albumin, complement 
C 3 , cholesterol, creatinine level). 
 2.5. Statistical analysis 
 Data are presented as  mean ±  SD . Means between 
two groups were compared using paired or unpaired 
Student’s  t tests, as appropriate. Non-parametric 
data were compared using Pearson  χ 2 tests or 
Fisher’s exact tests. The 95% confidence intervals 
were calculated as appropriate. Linear correlation 
and regression analyses were used to test the cor-
relations between increased RV filling pressure and 
the independent variables. The Mann-Whitney U test 
was used to compare data that were not normally 
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distributed. SPSS 11.0 (SPSS Inc., Chicago, IL, USA) 
was used for the analysis. A  p value of less than 
0.05 was regarded as significant. 
 3. Results 
 3.1. Clinical features 
 All children in the study group were considered to 
have PNS. Thirty-eight patients were at PNS onset; 
12 patients were in relapse after remission. The 
time from onset of the disease ranged from 1 day 
to 9 years, with a median of 4.5 weeks. At the time 
of admission, all patients had edema, heavy pro-
teinuria ( >  1.0 g/m 2 /day), hypoalbuminemia [serum 
albumin < 2.5 g/dL (25 g/L)] and hypercholesterole-
mia. Serum creatinine ranged from 40−116 μmol/L. 
Total platelet count averaged 323  × 10 9 /L ( ±  97  × 
10 9 /L), and the prothrombin time was 13.3 ±  1.4 
seconds. Chest radiography revealed that 31 pa-
tients had pulmonary congestion. A total of 41 pa-
tients responded during initial treatment; nine 
were steroid-resistant. In steroid-resistant patients, 
data from percutaneous kidney biopsies were only 
available in three patients: two indicated mem-
branoproliferative glomerulonephritis and one had 
FSGS. Intravenous pulse methylprednisolone and 
cyclophosphamide were used in 14 and 7 patients, 
respectively. No patients received any medication 
for their systemic hypertension. ECG was abnormal 
in 27 patients: of these, 15 had frequent ventricular 
or atrial ( n = 3) premature beats, and 12 had ST- or 
T-wave changes. In comparison to normal controls, 
patients with PNS had a larger RV dimension by 
echocardiography, and higher systolic and diastolic 
blood pressures. 
 RV function was determined by recording pressure-
volume loops. In the 50 patients with PNS, RV end-
diastolic pressure was raised by an average of 20% 
in 39 patients, whereas RV ejection fraction was 
reduced by an average of 15% compared with con-
trols ( p < 0.05 for both). Cardiac output and stroke 
volume were maintained, indicating compensation 
at the expense of increased RV end-diastolic and end-
systolic volumes and increased RV filling pressure 
( p < 0.05). 
 Plasma TNF- α was elevated in patients with PNS 
(326 ±  117 kU/L  vs. 75 ±  23 kU/L, p < 0.05); IGF-1 
levels were similar in PNS patients and controls 
(Table 1). 
 3.2.  Relationships between RV function 
and risk factors for PNS 
 We investigated the relationships between the var-
ious risk factors for PNS and RV function. Assuming 
that all patients with no tricuspid regurgitation or 
with immeasurable regurgitation had normal RV end-
diastolic pressure, the clinical features of patients 
with increased RV end-diastolic pressure are com-
pared with those with normal RV end-diastolic 
pressure in Table 2. Patients with increased RV 
end-diastolic pressure had a longer duration since 
Table 1  Clinical and echocardiographic data of 50 children with primary nephrotic syndrome (PNS) and 30 controls*
 Patients with PNS (n = 50) Controls (n = 30) p
Age (yr) 7.2 ± 3.3 7.9 ± 3.5 0.73
Heart rate (beats/min) 96 ± 18 92 ± 13 0.25
SBP (mmHg) 111 ± 15 90 ± 12 < 0.05
DBP (mmHg) 73 ± 14 62 ± 10 < 0.05
Left atrial dimension (mm) 25.1 ± 3.6 20.7 ± 2.6 < 0.01
LVEDD (mm) 34.9 ± 5.5 35.9 ± 6.4 0.89
RVEDD (mm) 12.7 ± 2.6 11.9 ± 2.5 0.038
Ppeak (mmHg) 42 ± 15 33 ± 6 < 0.01
PES (mmHg) 35 ± 14 29 ± 7 0.32
PED (mmHg) 6.1 ± 2.4 3.9 ± 2.5 < 0.01
dP/dtMax (mmHg/s) 2473 ± 778 2709 ± 790 0.76
dP/dtMin (mmHg/s) 1781 ± 675 1668 ± 428 0.69
LVEF (%) 72.8 ± 5.8 78.3 ± 8.0 0.19
RVEF (%) 59.6 ± 4.3 72.0 ± 2.9 < 0.05
TNF-α (kU/L) 226 ± 87 75 ± 23 < 0.05
IGF-1 (nmol/L) 24.5 ± 7.1 21.9 ± 6.0 0.32
*Data presented as mean ± SD. SBP = systolic blood pressure; DBP = diastolic blood pressure; LVEDD = left ventricular end diastolic 
dimension; RVEDD = right ventricular end diastolic dimension; Ppeak = RV peak pressure; PES = right ventricular end-systolic pressure; 
PED = right ventricular end-diastolic pressure; dP/dtmax = maximal rate of pressure increase; dP/dtmin = maximal rate of pressure 
decline; LVEF = left ventricular ejection fraction; RVEF = right ventricular ejection fraction; TNF-α = tumor necrosis factor-α; 
IGF-1 = insulin-like growth factor-1.
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disease onset ( p = 0.015) and a higher plasma TNF-
 α level ( p < 0.01). There were no differences in 
terms of age, steroid dependence, steroid resistance 
(Table 3), biochemical indicators of PNS and coag-
ulation, or the presence of pulmonary congestion 
( p > 0.05 for all). Further comparisons between the 
two groups with respect to cardiac signs and car-
diac laboratory test results found no significant 
differences in left ventricular systolic or diastolic 
function, BP or any other parameters. RV systolic 
pressure only correlated weakly with RV dimension 
( r = 0.44,  p < 0.05). There were no correlations be-
tween RV systolic pressure and any biochemical in-
dicators of PNS or coagulation ( p > 0.05 for all). 
 4. Discussion 
 Patients with chronic renal failure (CRF) manifest 
increased cardiac morbidity and mortality compared 
with age-matched controls. This is mainly due to 
hypertension, electrolyte disorders, volume overload 
and anemia. 8 Indices of altered renal function such 
as microalbuminuria, overt proteinuria, increased 
serum creatinine concentration, or reduced esti-
mated glomerular filtration rate are independent 
predictors of cardiac morbidity and mortality. 9,10 
Most of the clinical observations of cardiac compli-
cations of CRF have been made in adults, especially 
those with diabetes mellitus and hypertension. 
Table 2  Comparison of cardiac examination results between patients with increased and those with normal right 
ventricle end-diastolic pressure (RVEDP)*
 Patients with increased Patients without increased 
p
 RVEDP (n = 39) RVEDP (n = 11)
Heart rate (beats/min) 102 ± 19 99 ± 20 0.819
SBP (mmHg) 116 ± 18 108 ± 15 0.734
DBP (mmHg) 76 ± 14 77 ± 17 0.898
Abnormal ECG changes 22 (56.4%) 5 (45.5%) 0.434
Left atrial dimension (mm) 26.2 ± 2.8 23.4 ± 2.3 0.355
LVEDD (mm) 36.4 ± 5.5 34.9 ± 4.8 0.447
RVEDD (mm) 13.7 ± 2.6 12.3 ± 2.0 0.064
LVEF (%) 69.7 ± 4.8 71.4 ± 4.4 0.316
RVEF (%) 60.1 ± 4.3 58.9 ± 3.8 0.545
TNF-α (kU/L) 257 ± 97 198 ± 67 < 0.01
IGF-1 (nmol/L) 24.9 ± 3.1 24.4 ± 6.4 0.510
Duration since onset (wk)  115 ± 35 24 ± 6 0.015
Steroid resistant (n) 7 2 0.478
*Data presented as mean ± SD, n (%) or n. SBP = systolic blood pressure; DBP = diastolic blood pressure; ECG = electrocardiography; 
LVEDD = left ventricular end diastolic dimension; LVEF = left ventricular ejection fraction; RVEF = right ventricular ejection fraction; 
RVEDD = right ventricular end diastolic dimension; TNF-α = tumor necrosis factor-α; IGF-1 = insulin-like growth factor-1.
Table 3  Clinical and echocardiographic data of 50 children with nephrotic syndrome in relation to steroid respon-
siveness*
 Non-steroid Steroid dependent Steroid resistant
 dependent (n = 36) (n = 5) (n = 9)
Age (yr) 5.3 ± 3.6 6.0 ± 4.5 6.1 ± 3.3
Heart rate (beats/min) 95 ± 19 94 ± 17 98 ± 18
SBP (mmHg) 102 ± 14 110 ± 18 111 ± 22
DBP (mmHg) 75 ± 16 82 ± 18 85 ± 19
Left atrial dimension (mm) 23.4 ± 2.5 25.7 ± 3.0 26.1 ± 3.4
LVEDD (mm) 33.6 ± 4.6 35.8 ± 6.6 37.1 ± 6.0
RVEDD (mm) 10.9 ± 2.5 11.0 ± 3.0 11.2 ± 3.1
TNF-α (kU/L) 45 ± 19 44 ± 17 47 ± 17
IGF-1 (nmol/L) 5.1 ± 2.1 5.0 ± 1.7 4.8 ± 2.0
LVEF (%) 68.6 ± 6.2 72.3 ± 8.0 71.8 ± 7.9
RVEF (%) 59.1 ± 3.5 62.3 ± 4.9 61.7 ± 5.5
*Data presented as mean ± SD. SBP = systolic blood pressure; DBP = diastolic blood pressure; LVEDD = left ventricular end diastolic 
dimension; RVEDD = right ventricular end diastolic dimension; TNF-α = tumor necrosis factor-α; IGF-1 = insulin-like growth factor-1; 
LVEF = left ventricular ejection fraction; RVEF = right ventricular ejection fraction.
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Cardiac disease in these patients mostly takes the 
form of myocardial infarction. The emerging impor-
tance of cardiac disease in children and young adults 
with end-stage renal disease is highlighted by a re-
cent report indicating that cardiovascular deaths 
accounted for 23% of the mortality in this popula-
tion. 11 However, the relationship between cardiac 
disease and CRF and the various types of PNS, in 
particular, has not been sufficiently studied in pedi-
atric patients. In the present study, we evaluated RV 
function in children with PNS using Doppler echocar-
diography. Apart from RV hypertrophy, the primary 
cardiac response in PNS was RV dysfunction, that 
is, increased RV end-diastolic volume and pressure 
with consequent reductions in RV ejection fraction. 
This indicated that pulmonary arterial pressure was 
increased in patients with PNS. 
 The etiologies of RV dysfunction in children with 
PNS have been unclear until recently. However, the 
current study demonstrated that increased RV peak 
pressure and RV end-diastolic pressure were asso-
ciated with a longer time since disease onset, 
though no other factors predictive of or related to 
increased RV peak pressure and RV end-diastolic 
pressure could be identified in children with PNS. 
However, we suggest that increased RV peak pres-
sure and RV end-diastolic pressure in children with 
PNS could be ascribed to the following: 
 First, impaired functional reserve was high-
lighted by hemodynamic stress with increased RV 
end-diastolic pressure. Acute afterload elevations 
would result in decreased relaxation rate and in-
creased diastolic intolerance to afterload in chil-
dren with PNS. The hemodynamic disturbance was 
caused by increased diastolic intolerance to after-
load. This response to acute afterload can be a pre-
cocious sign of dysfunction, preceding overt heart 
failure. 12 
 Second, the elevated RV peak pressure and RV 
end-diastolic pressure could be caused by pulmo-
nary arterial hypertension. Hypercoagulability can 
be caused by profound abnormalities in almost all 
coagulation factors and clotting inhibitors, as well 
as by defects in platelets and the fibrinolytic sys-
tem. Although pulmonary embolism appears to be 
rarer in children than in adults, 2 its incidence might 
be underestimated because of the high number of 
asymptomatic or subclinical events in children with 
PNS. 13 Even in adults, as many as 50% of episodes 
of acute pulmonary thromboembolism remain un-
detected because their clinical presentation mim-
ics the characteristics of a number of other disease 
entities, and the sensitivity and specificity of diag-
nostic tests for pulmonary embolization remain 
either weak or poorly defined. 14 It is therefore pos-
sible that some of our patients might have devel-
oped pulmonary embolism either during or before 
the present episode of PNS. Our results were un-
able to identify any relationship between increased 
pulmonary pressure and the biochemical indica-
tors of thromboembolism studied. This could be 
because of wide variations in these indicators, or 
because of the small number of patients with in-
creased pulmonary pressure. 
 Systemic hypertension is a third possible expla-
nation for the increased RV peak pressure and RV 
end-diastolic pressure observed in children with 
PNS. BP was higher in children with PNS compared 
with controls. Sustained systemic hypertension has 
been shown to be a risk factor for increased pulmo-
nary arterial pressure. 15 However, our results failed 
to detect any significant difference in blood pressure 
between patients with normal RV peak pressure 
and RV end-diastolic pressure, and those with in-
creased RV peak pressure and RV end-diastolic pres-
sure. Thus, the duration of systemic hypertension 
might be a more important contributory factor in the 
increased RV peak pressure and RV end-diastolic 
pressure than the BP itself, because patients with 
increased RV peak pressure and RV end-diastolic 
pressure had longer durations since PNS onset. 
 Cardiac edema could also account for myocar-
dial dysfunction. Cardiac edema has been shown 
to increase myocardial stiffness and induce con-
tractile dysfunction. This has been attributed to 
increased myocardial expression of aquaporins. 16 
We cannot exclude the possibility that sympathetic 
activity may have influenced heart function in this 
study. Further studies are needed to determine the 
role of sympathetic activity. Additionally, regarding 
the role of proinflammatory cytokines, TNF- α levels 
were upregulated in the children with PNS. These 
observations mimic the pattern of cytokine activa-
tion observed in the glomeruli of rats injected with 
puromysin aminonucleoside, and might partly be 
explained by the increased circulating levels of TNF-
 α reported in PNS or the self-induction of TNF- α even 
in remote organs. 17−20 Local production of proinflam-
matory cytokines such as TNF-  α in the heart is poten-
tially relevant, given its well-known role in cardiac 
remodeling and contractile dysfunction. 21,22 More-
over, TNF-  α is a major determinant of cachexia in 
several chronic diseases. 23,24 Disturbed cardiomyo-
cyte calcium kinetics have also been implicated 
in myocardial dysfunction during heart failure pro-
gression. 12 No changes in circulating levels of IGF-1 
were detected in the current study, suggesting that 
this pleiotropic growth factor is not involved in car-
diac remodeling. Given that anorexia contributes 
to the malnutrition observed in PNS, the control of 
food intake might also be a relevant factor. 25 
 In conclusion, the results of this study showed 
that increased RV peak pressure and RV end-
diastolic pressure occurred in 78% of children with 
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PNS, together with elevated plasma TNF- α levels. 
Further studies are needed to understand the eti-
ology, clinical implications, and long term progno-
sis of this abnormality. 
 References 
 1. Citak A, Emre S, Sairin A, et al. Hemostatic problems and 
thromboembolic complications in nephrotic children. 
Pediatr Nephrol 2000;14:138−42. 
 2. Lilova MI, Velkovski IG, Topalov IB. Thromboembolic com-
plications in children with nephrotic syndrome in Bulgaria 
(1974−1996).  Pediatr Nephrol 2000;15:74−8. 
 3. Olanrewaju A, Rachel F, Suzanne V, et al. Cardiac disease 
in children with primary glomerular disorders—role of focal 
segmental glomerulosclerosis. Pediatr Nephrol 2004;19:
408−12. 
 4. Gerald F, Susan H, Gursharan K, et al. Vascular function of the 
peripheral circulation in patients with nephrosis.  Kidney 
Int 2001;60:182−9. 
 5. International Study of Kidney Disease in Children. Nephrotic 
syndrome in children: prediction of histopathology from 
clinical and laboratory characteristics at the time of diag-
nosis.  Kidney Int 1978;13:159−65. 
 6. British Association for Paediatric Nephrology and Royal 
College of Physicians. Consensus statement on manage-
ment and audit potential for steroid responsive nephrotic 
syndrome. Report of a Workshop by the British Association 
for Paediatric Nephrology and Research Unit, Royal College 
of Physicians.  Arch Dis Child 1994;70:151−7. 
 7. Leeuwenburgh BP, Steendijk P, Helbing WA, et al. Indexes of 
diastolic RV function: load dependence and changes after 
chronic RV pressure overload in lambs.  Am J Physiol Heart 
Circ Physiol 2002;282:H1350−8. 
 8. Hannedouche T, Bouiller M, Caillard S. Absolute cardiovas-
cular risk among nephrology patients.  Nephrologie 1998;
19:197−201. [In French] 
 9. Segura J, Campo C, Ruilope LM. Proteinuria: an underappre-
ciated risk factor in cardiovascular disease.  Curr Cardiol 
 Rep 2002;4:458−62. 
 10. Ritz E, Dikow R, Ruilope LM. Renal dysfunction as a cardio-
vascular risk factor.  Curr Hypertens 2002;Rep 4:365−8. 
 11. Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular 
mortality in children and young adults with end stage kidney 
disease.  J Pediatr 2002;141:191−7. 
 12. Correia Pinto J, Henriques-Coelho T, Roncon-Albuquerque 
Jr R, et al. Differential right and left ventricular diastolic 
tolerance to acute afterload and NCX gene expression in 
Wistar rats.  Physiol Res 2006;55:513−26. 
 13. Yock PG, Popp RL. Noninvasive estimation of right ven-
tricular systolic pressure by Doppler ultrasound in patients 
with tricuspid regurgitation.  Circulation 1984;70:657−62. 
 14. Eterson KL. Acute pulmonary thromboembolism: has its 
evolution been redefined?  Circulation 1999;99:1280−3. 
 15. Alpert MA, Bauer JH, Parker BM, et al. Pulmonary hemody-
namics in systemic hypertension. Long-term effect of 
minoxidil.  Chest 1979;76:379−83. 
 16. Egan JR, Butler TL, Au CG, et al. Myocardial water handling 
and the role of aquaporins. Biochim Biophys Acta 2006;
1758:1043−52. 
 17. Gomez-Chiarri M, Ortiz A, Lerma JL, et al. Involvement of 
tumor necrosis factor and platelet-activating factor in the 
pathogenesis of experimental nephrosis in rats.  Lab Invest 
1994;70:449−59. 
 18. Bustos C, Gonzalez E, Muley R, et al. Increase of tumour 
necrosis factor alpha synthesis and gene expression in 
peripheral blood mononuclear cells of children with idio-
pathic nephrotic syndrome.  Eur J Clin Invest 1994;24:
799−805. 
 19. Suranyi MG, Guasch A, Hall BM, et al. Elevated levels of 
tumor necrosis factor-alpha in the nephrotic syndrome in 
humans.  Am J Kidney Dis 1993;21:251−9. 
 20. Nakamura H, Umemoto S, Naik G, et al. Induction of left 
ventricular remodeling and dysfunction in the recipient 
heart after donor heart myocardial infarction: new insights 
into the pathologic role of tumor necrosis factor-alpha 
from a novel heterotopic transplant-coronary ligation rat 
model.  J Am Coll Cardiol 2003;42:173−81. 
 21. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis 
factor-alpha and tumor necrosis factor receptors in the 
failing human heart.  Circulation 1996;93:704−11. 
 22. Torre-Amione G, Kapadia S, Lee J, et al. Expression and 
functional significance of tumor necrosis factor receptors 
in human myocardium. Circulation 1995;92:1487−93. 
 23. Jackman RW, Kandarian SC. The molecular basis of skeletal 
muscle atrophy.  Am J Physiol Cell Physiol 2004;287:
C834−43. 
 24. Moldawer LL, Copeland III EM. Proinflammatory cytokines, 
nutritional support, and the cachexia syndrome: interac-
tions and therapeutic options.  Cancer 1997;79:1828−39. 
 25. Dong F, Ren J. Insulin-like growth factors (IGFs) and IGF-
binding proteins in nephrotic syndrome children on gluco-
corticoid.  Pharmacol Res 2003;48:319−23. 
